Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 123

1.

Spontaneous nasal perforation in a bevacizumab-treated patient with metastatic breast cancer.

Rodriguez CA, Martin T, Lozano R, Gomez A, Cruz JJ.

Breast J. 2017 Nov;23(6):745-746. doi: 10.1111/tbj.12913. Epub 2017 Aug 27.

PMID:
28845572
2.

[Perforation of the nasal septum: a rare complication of bevacizumab].

Bylicki O, Boursier C, Peloni JM, Dot JM.

Rev Mal Respir. 2012 Nov;29(9):1124-6. doi: 10.1016/j.rmr.2012.04.011. Epub 2012 Jul 31. French.

PMID:
23200586
3.

[Nasal septum perforation and bevacizumab].

Bengrine-Lefevre L, Afchain P, Chibaudel B, Gervais H, Tournigand C, De Gramont A, Louvet C.

Rev Med Interne. 2011 Apr;32(4):e43-5. doi: 10.1016/j.revmed.2010.04.015. Epub 2010 Jun 17. French.

PMID:
21470582
4.

An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

D'Amico M, Pagano M, Pasa A, Puntoni M, Clavarezza M, Gennari A, Gozza A, Zanardi S, Defferrari C, Provinciali N, Campazzi E, Campora S, Paleari L, Marra D, Petrera M, DeCensi A.

Expert Opin Drug Saf. 2014 Nov;13(11):1437-42. doi: 10.1517/14740338.2014.960388. Epub 2014 Sep 16.

PMID:
25224760
5.

Nasal septal perforation secondary to systemic bevacizumab.

Geltzeiler M, Steele TO.

Am J Otolaryngol. 2017 May - Jun;38(3):354-355. doi: 10.1016/j.amjoto.2017.01.018. Epub 2017 Jan 19.

PMID:
28215816
6.

Nasal septal perforation from bevacizumab: a discussion of outcomes, management, and pharmacovigilance.

Ramiscal JA, Jatoi A.

Curr Oncol Rep. 2012 Aug;14(4):307-10. doi: 10.1007/s11912-012-0236-x. Review.

PMID:
22544558
7.

Grade 4 epistaxis in a woman with metastatic breast cancer treated with bevacizumab: a case report.

Yanagihara K, Takei H, Iida S, Yamashita K, Kurita T, Iwamoto M, Saegusa H, Uchida E.

J Nippon Med Sch. 2014;81(5):333-6.

8.

Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer.

Traina TA, Norton L, Drucker K, Singh B.

Oncologist. 2006 Nov-Dec;11(10):1070-1. No abstract available.

9.

Paclitaxel plus bevacizumab or paclitaxel as first-line treatment for HER2-negative metastatic breast cancer in a multicenter national observational study.

Delaloge S, Pérol D, Courtinard C, Brain E, Asselain B, Bachelot T, Debled M, Dieras V, Campone M, Levy C, Jacot W, Lorgis V, Veyret C, Dalenc F, Ferrero JM, Uwer L, Kerbrat P, Goncalves A, Mouret-Reynier MA, Petit T, Jouannaud C, Vanlemmens L, Chenuc G, Guesmia T, Robain M, Cailliot C.

Ann Oncol. 2016 Sep;27(9):1725-32. doi: 10.1093/annonc/mdw260. Epub 2016 Jul 19.

PMID:
27436849
10.

A patient presenting nasal septum perforation during bevacizumab-containing chemotherapy for advanced breast cancer.

Petrelli F, Cabiddu M, Barbara C, Barni S.

Breast Cancer. 2011 Jul;18(3):226-30. doi: 10.1007/s12282-011-0255-8. Epub 2011 Feb 11. Review.

PMID:
21312011
11.

Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.

Fujii Y, Hirahara N, Kaji S, Taniura T, Hyakudomi R, Yamamoto T, Tajima Y.

J Med Case Rep. 2018 Mar 27;12(1):84. doi: 10.1186/s13256-018-1619-x. Review.

12.

Dynamic Contrast-enhanced Magnetic Resonance Imaging for Patients with Breast Cancer Receiving First-line Bevacizumab and Paclitaxel.

Nakatsukasa K, Ouchi Y, Sakaguchi K, Goto M, Konishi E, Taguchi T.

Anticancer Res. 2018 Sep;38(9):5459-5463. doi: 10.21873/anticanres.12878.

PMID:
30194203
13.

[Usefulness of bevacizumab combination chemotherapy for advanced breast cancer].

Aomatsu N, Kashiwagi S, Morisaki T, Ishihara S, Asano Y, Watanabe M, Noda S, Kawajiri H, Takashima T, Onoda N, Ishikawa T, Hirakawa K.

Gan To Kagaku Ryoho. 2013 Nov;40(12):2393-5. Japanese.

PMID:
24394123
15.

Fatal hemoptysis in a patient with breast cancer treated with bevacizumab and paclitaxel.

Philippin-Lauridant G, Thureau S, Ouvrier MJ, Blot E.

Ann Oncol. 2008 Nov;19(11):1977-8. doi: 10.1093/annonc/mdn641. Epub 2008 Sep 18. No abstract available.

PMID:
18801882
16.

[Safety and efficacy of bevacizumab combined with taxanes in the first-line treatment of metastatic breast cancer: ATHENA study-France].

Hardy-Bessard AC, Delva R, Pivot X, Espié M, Dalenc F, Coulon Sfairi MA, Monnier A, Serin D, Veyret C, Lortholary A, Pavlyuk M, Kockler L, Pierga JY.

Bull Cancer. 2012 Jun;99(6):609-18. doi: 10.1684/bdc.2012.1586. French.

17.

Bronchoesophageal fistula and fatal hemoptysis after bevacizumab-containing chemotherapy without radiation in lung cancer.

Schreiber J, Waldburg N.

J Clin Oncol. 2012 Nov 10;30(32):e324. doi: 10.1200/JCO.2012.42.8169. Epub 2012 Sep 24. No abstract available.

PMID:
23008311
18.

First-line bevacizumab in combination with weekly paclitaxel for metastatic breast cancer: efficacy and safety results from a large, open-label, single-arm Japanese study.

Aogi K, Masuda N, Ohno S, Oda T, Iwata H, Kashiwaba M, Fujiwara Y, Kamigaki S, Ito Y, Ueno T, Takashima S.

Breast Cancer Res Treat. 2011 Oct;129(3):829-38. doi: 10.1007/s10549-011-1685-x. Epub 2011 Jul 31.

PMID:
21805309
19.

[Efficacy of bevacizumab in combination with paclitaxel for metastatic breast cancer].

Suzuki S, Sakurai K, Nagashima S, Hara Y, Amano S, Enomoto K, Makishima M.

Gan To Kagaku Ryoho. 2014 Oct;41(10):1289-91. Japanese.

PMID:
25335720
20.

[Intestinal perforation: an unusual adverse event of bevacizumab and paclitaxel combined therapy for a metastatic breast cancer].

Mychaluk J, Piprot C, Sevestre H, Merviel P, Gondry J, Fauvet R.

Presse Med. 2009 Sep;38(9):1370-4. doi: 10.1016/j.lpm.2008.10.020. Epub 2009 Apr 5. French. No abstract available.

PMID:
19349140

Supplemental Content

Support Center